Skip to main content

Table 1 Baseline clinical characteristics of 50 GIST patients treated with regorafenib

From: Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre

CharacteristicTotal, n = 50
Age at diagnosis (years) 
 Median (IQR)56.0 years (46.0–66.5 years)
Gender 
 Female18 (36%)
 Male32 (64%)
Primary site 
 Stomach21 (42%)
 Small bowel21 (42%)
 Large bowel2 (4.0%)
 Rectum2 (4.0%)
 Mesenteric2 (4.0%)
 Oesophageal2 (4.0%)
Line of treatment (regorafenib) 
 3rd line38 (76%)
 4th line10 (20%)
 ≥ 5th line2 (4%)
Tumour size (cm) 
 Median (IQR)12.0 (8.0–17.0)
Mutation profile 
 KIT31 (62%)
  Exon 94 (8%)
  Exon 1124 (48%)
  Exon 11 + 131 (2%)
  Exon 11 + 172 (4%)
 PDGFR6 (12%)
  Exon 185 (10%)
  Exon 12 + 181 (2%)
 WT4 (8%)
 Unknown9 (18%)
Reason for discontinuing regorafenib 
 Progressive disease31 (62%)
 Toxicity10 (20%)
 New comorbidity/contraindication3 (6%)
 Death2 (4%)
 Surgery planned1 (2%)
 Withdrawal of consent to treatment1 (2%)
 N/A—patient continues regorafenib2 (4%)
AE 
 Grade ≥ 323 (46%)
Best response as per RECIST 1.1 
 Stable disease35 (70%)
 Partial response4 (8%)
 Progressive disease4 (8%)
 Complete response0 (0%)
 Not evaluable7 (14%)